Jose A Obeso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5744288/publications.pdf

Version: 2024-02-01

70 5,429 30 62
papers citations h-index g-index

72 72 72 6988
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease. Movement Disorders, 2022, 37, 279-290.	3.9	23
2	Neuron types in the primate striatum: Stereological analysis of projection neurons and interneurons in control and parkinsonian monkeys. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	10
3	Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism. Neurobiology of Disease, 2022, 167, 105669.	4.4	5
4	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. Nature Reviews Neuroscience, 2022, 23, 115-128.	10.2	92
5	Striatal <scp>Blood–Brain</scp> Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study. Movement Disorders, 2022, 37, 2057-2065.	3.9	25
6	Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia. Nature Communications, 2021, 12, 779.	12.8	134
7	Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 927-931.	1.9	31
8	Present and future of subthalamotomy in the management of Parkinson´s disease: a systematic review. Expert Review of Neurotherapeutics, 2021, 21, 533-545.	2.8	9
9	Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients. Movement Disorders, 2021, 36, 1994-1995.	3.9	0
10	Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First. Movement Disorders, 2021, 36, 905-915.	3.9	21
11	Focused ultrasound thalamotomy for multiple sclerosis–associated tremor. Multiple Sclerosis Journal, 2020, 26, 855-858.	3.0	14
12	Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease. Neuropharmacology, 2020, 170, 107806.	4.1	12
13	Functional impact of subthalamotomy by magnetic resonance–guided focused ultrasound in Parkinson's disease: a hybrid PET/MR study of resting-state brain metabolism. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 425-436.	6.4	23
14	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 437-450.	6.4	54
15	Changes in Thalamic Dopamine Innervation in a Progressive Parkinson's Disease Model in Monkeys. Movement Disorders, 2020, 35, 419-430.	3.9	23
16	Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease. New England Journal of Medicine, 2020, 383, 2501-2513.	27.0	111
17	Cortical disinhibition in Parkinson's disease. Brain, 2020, 143, 3408-3421.	7.6	47
18	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain, 2020, 143, 1462-1475.	7.6	135

#	Article	IF	CITATIONS
19	Understanding motor control in health and disease: classic single (n = 1) observations. Experimental Brain Research, 2020, 238, 1593-1600.	1.5	8
20	Editor's Note: Pathophysiology of the Basal Ganglia Grows in Understanding and Complexity but Essential Unknown Remains. Movement Disorders, 2019, 34, 1128-1129.	3.9	3
21	Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Movement Disorders, 2019, 34, 1262-1273.	3.9	25
22	Editor's note: Functional movement disorders: The pendulum keeps moving. Movement Disorders, 2019, 34, 970-970.	3.9	2
23	Editor's Note: The Beauty and Convenience of Simplicity: Will It Help Enlighten Our Understanding of Progressive Supranuclear Palsy?. Movement Disorders, 2019, 34, 1283-1283.	3.9	0
24	Editor's note: Huntington's disease: One gene, one protein, one effective therapy. What is wrong (or) Tj ETQq0 (OggBT/C	verlock 10 Tf
25	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	3.9	62
26	Editor's note: The origin of Parkinson's disease: The importance of environment and lifestyle. Movement Disorders, 2019, 34, 799-800.	3.9	0
27	Editor's note: Prodromal Parkinson's disease. Movement Disorders, 2019, 34, 664-664.	3.9	2
28	Dopaminergic Vulnerability in Parkinson Disease: The Cost of Humans' Habitual Performance. Trends in Neurosciences, 2019, 42, 375-383.	8.6	24
29	Movement disorders journal conference 2018: Neuronal vulnerability in Parkinson's disease. Movement Disorders, 2019, 34, 1405-1405.	3.9	0
30	The End of a Cycle: A Unique Perspective in the Evolution of <i>Movement Disorders</i> Disorders, 2019, 34, 1755-1757.	3.9	1
31	<i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. Movement Disorders, 2019, 34, 1814-1816.	3.9	1
32	Editor's Note: Deep Brain Stimulation and Functional Neurosurgery for Movement Disorders: Is the Current Cycle Waning?. Movement Disorders, 2019, 34, 1792-1794.	3.9	1
33	Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia. Brain Imaging and Behavior, 2019, 13, 180-188.	2.1	25
34	The use of nonhuman primate models to understand processes in Parkinson's disease. Journal of Neural Transmission, 2018, 125, 325-335.	2.8	19
35	Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurology, The, 2018, 17, 54-63.	10.2	163
36	A Cortical Pathogenic Theory of Parkinson's Disease. Neuron, 2018, 99, 1116-1128.	8.1	108

#	Article	IF	CITATIONS
37	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. Neurobiology of Aging, 2018, 70, 325.e1-325.e5.	3.1	6
38	Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 2017, 18, 101-113.	10.2	711
39	What <scp>W</scp> ould <scp>D</scp> r. <scp>J</scp> ames <scp>P</scp> arkinson <scp>T</scp> hink <scp>T</scp> oday? <scp>I</scp> . <scp>T</scp> he <scp>R</scp> ole of <scp>F</scp> unctional <scp>N</scp> eurosurgery for <scp>P</scp> arkinson's <scp>D</scp> isease. Movement Disorders, 2017, 32. 2-4.	3.9	20
40	Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification. Experimental Neurology, 2017, 298, 148-161.	4.1	175
41	Parkinson's Disease Is Not Simply a Prion Disorder. Journal of Neuroscience, 2017, 37, 9799-9807.	3.6	144
42	Unilateral subthalamotomy in Parkinson's disease: Cognitive, psychiatric and neuroimaging changes. Cortex, 2017, 94, 39-48.	2.4	16
43	Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Human Brain Mapping, 2016, 37, 968-977.	3.6	40
44	Parkinson's disease and thalamus: facts and fancy. Lancet Neurology, The, 2016, 15, e2.	10.2	8
45	The subthalamic nucleus and inhibitory control: impact of subthalamotomy in Parkinson's disease. Brain, 2014, 137, 1470-1480.	7.6	86
46	Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum. Journal of Neuroscience, 2014, 34, 8210-8218.	3.6	136
47	The expanding universe of disorders of the basal ganglia. Lancet, The, 2014, 384, 523-531.	13.7	155
48	Longitudinal Assessment of the Pattern of Cognitive Decline in Non-Demented Patients with Advanced Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 677-686.	2.8	32
49	The state of the journal—2013. Movement Disorders, 2013, 28, 259-260.	3.9	0
50	Commentary on reversible pseudoathetosis induced by cervical myelopathy. Movement Disorders, 2012, 27, 1371-1371.	3.9	1
51	Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. Frontiers in Systems Neuroscience, 2011, 5, 92.	2.5	48
52	New Sections for <i>Movement</i> Disorders. Movement Disorders, 2011, 26, 2179-2179.	3.9	0
53	In Vivo Growing of New Cell Colonies in a Portion of Bone Marrow: Potential Use for Indirect Cell Therapy. Cell Medicine, 2010, 1, 93-104.	5.0	0
54	Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study. Neurobiology of Disease, 2010, 38, 456-463.	4.4	66

#	Article	IF	Citations
55	Longâ€term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Movement Disorders, 2010, 25, 578-586.	3.9	382
56	Reply to: "Being too inclusive about synuclein inclusions― Nature Medicine, 2010, 16, 961-961.	30.7	О
57	Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease. Movement Disorders, 2008, 23, S548-S559.	3.9	453
58	The basal ganglia in Parkinson's disease: Current concepts and unexplained observations. Annals of Neurology, 2008, 64, S30-S46.	5.3	205
59	The globus pallidus pars externa and Parkinson's disease. Ready for prime time?. Experimental Neurology, 2006, 202, 1-7.	4.1	31
60	How does Parkinson's disease begin? The role of compensatory mechanisms. Trends in Neurosciences, 2004, 27, 125-127.	8.6	65
61	The Basal Ganglia and Disorders of Movement: Pathophysiological Mechanisms. Physiology, 2002, 17, 51-55.	3.1	46
62	The contribution of C. David Marsden to the study and treatment of myoclonus. Advances in Neurology, 2002, 89, 1-12.	0.8	3
63	The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain, 2001, 124, 1777-1790.	7.6	417
64	The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain, 2001, 124, 5-19.	7.6	130
65	Pathophysiology of the basal ganglia in Parkinson's disease. Trends in Neurosciences, 2000, 23, S8-S19.	8.6	702
66	Letters to the editor. Movement Disorders, 1994, 9, 470-473.	3.9	8
67	Cortical mechanisms mediating asterixis. Movement Disorders, 1992, 7, 209-216.	3.9	23
68	Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Annals of Neurology, 1992, 31, 551-554.	5.3	69
69	Generalized reflex myoclonus in a patient with alcohol-sensitive spontaneous myoclonus and an abnormal gait. Movement Disorders, 1990, 5, 85-88.	3.9	8
70	Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Movement Disorders, 1990, 5, 170-172.	3.9	29